Navigation Links
Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis

: justify">

“This is a significant milestone for us. We are encouraged by the positive results from this study, which suggest HMPL-004 can be a novel class of anti-inflammatory drug for the treatment of Ulcerative Colitis. We believe that HMPL-004 has significant potential to bring patients another option for the treatment of this chronic, painful and frequently recurring disease, which may lead to abdominal surgery. We are looking forward to further clinical studies to fully evaluate the clinical benefits of HMPL-004. Today’s announcement further validates our new drug discovery and development capability and will also further accelerate recruitment in the on-going Phase II Crohn’s Disease trial in the US.”

Mr. Christian Hogg, CEO of Chi-Med, said:

“We are extremely pleased with the trial results, which fully meet our expectations. Ulcerative Colitis and Crohn’s Disease are core focus areas of our R&D programme, and we also look forward to the delivery of the Phase II results for HMPL-004 in Crohn’s Disease after which we would seek to out-license this product, in line with our stated strategy. Today’s results once more also highlight the potential of Traditional Chinese Medicine to provide a reservoir for innovative new drugs for the global pharmaceutical market.”

Ends

Enquiries
Chi-Med
Christian Hogg, CEO
Telephone: +852 2121 8200

Citigate Dewe Rogerson
Anthony Carlisle
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/22/2014)... PharmaTech (Cayman) Inc. (NYSE: WX ), a leading ... in China and the ... financial results for the second quarter of 2014 after the ... (which will be Thursday morning, August 14, 2014 Shanghai time). ... section of the Company,s website at http://www.wuxiapptec.com . ...
(Date:7/22/2014)... SOUTH EASTON, Mass. , July 22, ... ("PBI" or the "Company") and Parabase Genomics ... have entered into a strategic research and ... of the collaboration, PBI will develop a ... neonatal molecular diagnostics and newborn confirmatory testing ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Cheyenne Regional Medical Center is expanding its ... an AirLife Denver medical helicopter service in ... Regional and HCA-HealthONE, which operates AIRLIFE Denver. ... blue and sonic green helicopter will be stationed in ...
... Systems, Inc. (Nasdaq: DCTH ) announced today that ... Lazard Capital Markets, Eighth Annual Healthcare Conference on Tuesday, November ...  Mr. Hobbs will provide an overview of the Company,s business ... this conference is by invitation only.  Delcath will offer a ...
Cached Medicine Technology:Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 2Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONE's AirLife Denver 3Delcath to Present at the Lazard Healthcare Conference on November 15 2Delcath to Present at the Lazard Healthcare Conference on November 15 3
(Date:7/22/2014)... Aaron Marshall, Corporate Counsel at Northrop Grumman, will ... Agency for the 2014-2015 fiscal year. He joined the ... states, "“Serving on the HASA board has given me a ... me remember how much others need help." , ABOUT AARON ... has a B.S. in Finance from the University of Delaware. ...
(Date:7/22/2014)... Society of Hematology (ASH) will honor Tomas Ganz, MD, ... with the 2014 E. Donnall Thomas Lecture for his ... the iron-regulatory hormone hepcidin and investigation of its roles ... Prize Laureate and past Society president E. Donnall Thomas, ... represented a paradigm shift or significant discovery in the ...
(Date:7/22/2014)... at the University of Utah,s John A. Moran Eye ... Eye Research (ISER) as the recipient of the Houston, ... in Retina Research., The award recognizes lifetime achievement by ... to the understanding of vitreoretinal diseases or disorders. The ... Biennial Meeting in San Francisco, where Marc will deliver ...
(Date:7/22/2014)... As reported on July 17, 2014 by ABC News, ... favorite beauty products, “ Botox , that’s pretty much it.” ... has changed my life” by halving the amount of ... various, daily appearances. “Suddenly my eyelids are no longer ... “I think that Kelly Ripa’s response to the question was ...
(Date:7/22/2014)... American Conference on Lung Cancer (LALCA 2014) will be ... , Lung Cancer is still the leading cause of ... on the success of the previous conferences in Chile, ... discuss the science and advances in the treatment and ... Latin America in particular. , With tobacco being the ...
Breaking Medicine News(10 mins):Health News:New Board President for Baltimore-based Nonprofit 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2
... Dr. Lawyer will lead clinical efforts of the ... KePRO, a national medical,management firm, appointed Lenaye ... Dr. Lawyer will oversee all clinical aspects of ... Harrisburg,office., "Dr. Lawyer has practiced her entire ...
... the Northeast region with more hires,planned throughout the ... Aug. 28 The Pennsylvania,Patient Safety Authority has ... to help healthcare facilities that report to the,Pennsylvania ... Pennsylvania citizens., "Last year in focus groups ...
... 67%, but patients and doctors say drug is hard to ... percent of patients with atrial fibrillation, a known risk factor ... anti-clotting drug warfarin, a new study found. , Among those ... prevent a stroke. And an additional 25 percent were taking ...
... growing professional and consumer markets in China. , ... ... international venture capital firm, today announced that together with Mustang Ventures, ... of financing for Profex.Inc. Trident Capital & Mustang Ventures jointly invested ...
... HAYWARD, Calif., Aug. 28 Guava Technologies, Inc.,announced ... Group to,provide drug discovery researchers with an automated ... key component of a larger,strategic initiative by Guava ... voiced need for sophisticated cell analysis technology to,support ...
... increased plaque , , THURSDAY, Aug. 28 (HealthDay News) -- A ... in the brain that is thought to play a key ... the protein, known as amyloid beta, was directly linked to ... When brain cell communication increased, so did amyloid beta. When ...
Cached Medicine News:Health News:Lenaye Lawyer, MD, FACOG, Named KePRO Medical Director 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 2Health News:Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose 3Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 2Health News:Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc. 3Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 2Health News:San Francisco Bay Area Cell Analysis Company Forges Partnership With Hudson Control Group as First Step in Automation Initiative to Support Drug Discovery Research 3Health News:Scientists Track Hourly Changes in Alzheimer's Protein 2
Easy to use , Allow for a flexible washing , Uniform and efficient , Very robust and reliable , Adjustable to all well shapes , Rack included (not autoclavable) , Autoclavable at 121C , No e...
... with a 25-microplate capacity ... and aspiration and dispense ... On-board software for user ... programs. External vacuum pump ...
... microplate washers available to handle ... cell-based assays. Embla 384 Cell ... have been optimized to avoid ... robotic compatible and have been ...
ELISA Microplate Washer, Manual...
Medicine Products: